Navigation Links
Par Pharmaceutical Completes Acquisition of Anchen
Date:11/17/2011

WOODCLIFF LAKE, N.J., Nov. 17, 2011 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that it has completed its acquisition of Anchen Pharmaceuticals, a privately-held specialty pharmaceutical company focused on developing and commercializing extended release and niche generic products.

Headquartered in Irvine, California, Anchen is a profitable, fully-integrated pharmaceutical company with five commercialized products, 27 ANDAs on file with the US FDA, five of which are believed to be first-to-file, and approximately 26 additional products in development. Anchen has approximately 200 employees and over 72,000 sq. ft. of expandable manufacturing and warehouse facilities with state-of-the-art equipment.

The $410 million purchase price was financed with cash on hand and a $350 million term loan.

About Par Pharmaceutical Companies, Inc.

Par Pharmaceutical Companies, Inc. is a U.S.-based specialty pharmaceutical company. Through its wholly owned subsidiary's two operating divisions, Par Pharmaceutical and Strativa Pharmaceuticals, it develops, manufactures and markets higher-barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals. For press releases and other company information, visit http://www.parpharm.com.

Safe Harbor Statement

Certain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. To the extent any statements made in this news release contain information that is not historical, these statements are essentially forward-looking and, as such, are subject to known and unknown risks, uncertainties and contingencies, many of which are beyond the control of the Company, which could cause actual results and outcomes to differ materially from those expressed herein. Risk factors that might affect such forward-looking statements include those set forth in Item 1A of the Company's most recent Annual Report on Form 10-K, in other of the Company's filings with the SEC from time to time, including Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and on general industry and economic conditions. Any forward-looking statements included in this news release are made as of the date hereof only, based on information available to the Company as of the date hereof, and, subject to any applicable law to the contrary, the Company assumes no obligation to update any forward-looking statements.


'/>"/>
SOURCE Par Pharmaceutical Companies
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Avanir Pharmaceuticals Announces EMA Acceptance of Marketing Authorization Application for NUEDEXTA
2. Ampio Pharmaceuticals Expands Patent Portfolio of Drugs for Treating Inflammatory Diseases
3. Idenix Pharmaceuticals Prices Public Offering of Common Stock
4. Pacira Pharmaceuticals, Inc. Announces Pricing of Follow-On Offering
5. Pharmaceutical Investment & Cost Benchmarks Accessed Quickly Through Best Practices, LLCs New Database Search Function
6. Idenix Pharmaceuticals Announces Proposed Public Offering of Common Stock
7. Radient Pharmaceuticals Asks DHS Holding Co. to Retract News Release Saying It Will Enter Into Talks With Radient Pharmaceuticals Corporation
8. The Outlook for Pharmaceuticals in South East Asia
9. The Outlook for Pharmaceuticals in Western Europe
10. The Outlook for Pharmaceuticals in Central & Eastern Europe
11. The Outlook for Pharmaceuticals in the Middle East and North Africa
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... NEW YORK , Jan. 19, 2017 ... ... Forecast 2016-2026: Opportunities for Leading Companies – our new ... new report discusses issues and events affecting the Alzheimer,s ... qualitative analyses to answer these key questions: - How ...
(Date:1/19/2017)... , Jan. 19, 2017  Stealth BioTherapeutics Inc. ... to treat mitochondrial dysfunction, today announced new additions to ... M.D., as Chief Medical Officer, and Daniel Geffken ... announced that Jim Carr , Pharm.D. has been ... "We are pleased to welcome Doug and Daniel to ...
(Date:1/19/2017)... Accuray Incorporated (Nasdaq: ARAY ) ... to set the bar for excellence in customer satisfaction. ... satisfaction rating among radiation treatment delivery systems in the ... Intelligence Briefing™. The most recent ratings trend also shows ... peers for 11 of the past 12 quarters. ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... January 20, 2017 , ... Bionic Sports Nutrition LLC, an American company ... it had a successful January ECRM Trade Show in Hilton Head, SC. , ... allows it to provide its products to all clients at reasonable prices. At the ...
(Date:1/20/2017)... FL (PRWEB) , ... January 20, 2017 , ... ... and wellness products to enhance people’s everyday lives, recently attended the January ECRM ... buyers. , ATP Science is known for its large range of supplements that ...
(Date:1/20/2017)... florida (PRWEB) , ... January 20, 2017 , ... Michael ... the Dana Farber Cancer Institute. For Betsy, the clinical trial has been life-saving ... cancer has not worsened. , Betsy Brauser was diagnosed with ovarian cancer in ...
(Date:1/20/2017)... ... January 20, 2017 , ... Vitamin Well has launched ... The drinks have been produced in collaboration with Zlatan Ibrahimovic and have been ... , After a successful launch in Sweden last year, the next generation sports ...
(Date:1/20/2017)... ... ... “The Angel”: a heartwarming and earnest tale of faith and believing ... “The Angel” is the creation of published author, Marjorie Lund-Fontaine, a former professional violinist, ... , When asked of her new book, Marjorie says, “‘The Angel’ was written as ...
Breaking Medicine News(10 mins):